{
    "nct_id": "NCT05086705",
    "official_title": "Cool Down With EMBr: Enhancing Menopausal Hot Flash Symptom Reduction After Breast Cancer",
    "inclusion_criteria": "* Women with history of breast cancer, ductal breast carcinoma in situ (DCIS), or lobular breast carcinoma in situ (LCIS) (currently without evidence of malignant disease)\n* Bothersome hot flashes (defined by their occurrence of >= 28 times per week and of sufficient severity to prompt the patient to seek therapeutic intervention)\n* Presence of hot flashes for > 30 days prior to study entry\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willingness to wear EMBr Wave device during the study period\n* Willingness to use the EMBr Wave mobile application\n* Have a working smartphone that can download the EMBr Wave mobile application (iPhone 6 or more recent generation, Android 8.0 or more recent generation)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0, 1\n* Ability to provide informed written consent\n* Life expectancy >= 6 months\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Antineoplastic chemotherapy (anti-HER2 agents allowed) (current [=< 4 weeks prior] or planned therapy)\n* Androgens (current [=< 4 weeks prior] or planned therapy)\n* Systemic estrogens. Local vaginal estrogen preparations are allowed, but need to have been initiated for vulvo-vaginal atrophy at least 28 days prior, and must not be expected to stop or change the dose or frequency of the medication during the study period (current [=< 4 weeks prior] or planned therapy)\n* Progestogens (current [=< 4 weeks prior] or planned therapy)\n* Tamoxifen, raloxifene and aromatase inhibitors are allowed, but patient must have been on a constant dose for at least 28 days and must not be expected to stop the medication during the study period (current [=< 4 weeks prior] or planned therapy)\n* Selective serotonin reuptate inhibitors (SSRIs)/serotonin-norepinephrine reuptake inhibitor (SNRIs), when being used for hot flash management or other indications such as depression, is allowed, assuming the dose will remain unchanged for the study duration (current [=< 4 weeks prior] or planned therapy)\n* Gabapentin/pregabalin, when being used for hot flash management (use for other indications, such as pain, is allowed, assuming the dose will remain unchanged for the study duration) (current [=< 4 weeks prior] or planned therapy)\n* Clonidine (current [=< 4 weeks prior] or planned therapy)\n* Prior use of EMBr Wave\n* Nickel allergy\n* Pregnant or nursing women since the safety of device has not been established in this population",
    "miscellaneous_criteria": ""
}